Arbutus Biopharma ABUS Stock
Arbutus Biopharma Price Chart
Arbutus Biopharma ABUS Financial and Trading Overview
| Arbutus Biopharma stock price | 4.03 USD |
| Previous Close | 3.82 USD |
| Open | 3.82 USD |
| Bid | 2.78 USD x 200 |
| Ask | 4.68 USD x 200 |
| Day's Range | 3.65 - 3.89 USD |
| 52 Week Range | 3.5 - 5.45 USD |
| Volume | 2.13M USD |
| Avg. Volume | 5.09M USD |
| Market Cap | 594.78M USD |
| Beta (5Y Monthly) | 0.808 |
| PE Ratio (TTM) | 3.403509 |
| EPS (TTM) | 1.12 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.35 USD |
ABUS Valuation Measures
| Enterprise Value | 260.6M USD |
| Trailing P/E | 3.403509 |
| Forward P/E | -23.474855 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.2771845 |
| Price/Book (mrq) | 9.023256 |
| Enterprise Value/Revenue | 1.436 |
| Enterprise Value/EBITDA | 1.791 |
Trading Information
Arbutus Biopharma Stock Price History
| Beta (5Y Monthly) | 0.808 |
| 52-Week Change | -21.074% |
| S&P500 52-Week Change | 9.77% |
| 52 Week High | 5.45 USD |
| 52 Week Low | 3.5 USD |
| 50-Day Moving Average | 4.53 USD |
| 200-Day Moving Average | 4.48 USD |
ABUS Share Statistics
| Avg. Volume (3 month) | 5.09M USD |
| Avg. Daily Volume (10-Days) | 2.48M USD |
| Shares Outstanding | 153.29M |
| Float | 116.7M |
| Short Ratio | 4.4 |
| % Held by Insiders | 15.91% |
| % Held by Institutions | 65.57% |
| Shares Short | 19.89M |
| Short % of Float | 14.77% |
| Short % of Shares Outstanding | 9.98% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 121.17% |
| Operating Margin (ttm) | 80.14% |
| Gross Margin | 91.93% |
| EBITDA Margin | 80.16% |
Management Effectiveness
| Return on Assets (ttm) | 41.56% |
| Return on Equity (ttm) | 269.58% |
Income Statement
| Revenue (ttm) | 181.49M USD |
| Revenue Per Share (ttm) | 0.93 USD |
| Quarterly Revenue Growth (yoy) | -43.50% |
| Gross Profit (ttm) | 166.85M USD |
| EBITDA | 145.49M USD |
| Net Income Avi to Common (ttm) | 219.91M USD |
| Diluted EPS (ttm) | 1.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 337.49M USD |
| Total Cash Per Share (mrq) | 2.2 USD |
| Total Debt (mrq) | 3.31M USD |
| Total Debt/Equity (mrq) | 3.86 USD |
| Current Ratio (mrq) | 1.404 |
| Book Value Per Share (mrq) | 0.43 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 221M USD |
| Levered Free Cash Flow (ttm) | 334.96M USD |
Profile of Arbutus Biopharma
| Country | United States |
| State | PA |
| City | Warminster |
| Address | 701 Veterans Circle |
| ZIP | 18974 |
| Phone | 267 469 0914 |
| Website | https://www.arbutusbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 19 |
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Q&A For Arbutus Biopharma Stock
What is a current ABUS stock price?
Arbutus Biopharma ABUS stock price today per share is 4.03 USD.
How to purchase Arbutus Biopharma stock?
You can buy ABUS shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Arbutus Biopharma?
The stock symbol or ticker of Arbutus Biopharma is ABUS.
Which industry does the Arbutus Biopharma company belong to?
The Arbutus Biopharma industry is Biotechnology.
How many shares does Arbutus Biopharma have in circulation?
The max supply of Arbutus Biopharma shares is 153.29M.
What is Arbutus Biopharma Price to Earnings Ratio (PE Ratio)?
Arbutus Biopharma PE Ratio is 3.59821440 now.
What was Arbutus Biopharma earnings per share over the trailing 12 months (TTM)?
Arbutus Biopharma EPS is 1.12 USD over the trailing 12 months.
Which sector does the Arbutus Biopharma company belong to?
The Arbutus Biopharma sector is Healthcare.
Arbutus Biopharma ABUS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25366.09 USD — |
-0.39
|
8.86B USD — | 25068.28 USD — | 25597.23 USD — | — - | 8.86B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12491.48 USD — |
-0.35
|
— — | 12339.28 USD — | 12603.6 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7247.55 USD — |
-2.3
|
— — | 7246.35 USD — | 7373.62 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1372.96 USD — |
-1.99
|
— — | 1372.67 USD — | 1394.6 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
31344.11 USD — |
-0.38
|
— — | 30976.16 USD — | 31629.69 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
